28 Nov FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-based Chemotherapy for Metastatic Non-small Cell Lung Cancer (NSCLC)
In POSEIDON study, a treatment-naive patients with metastatic non-small cell lung cancer (NSCLC), tremelimumab (anti-CTLA-4 antibody) plus durvalumab (anti-PD-L1 antibody) and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in median Overall Survival (OS) [14 months vs 11.7 months] and median Progression Free...